Search

Your search keyword '"Fay, Andre P."' showing total 135 results
Start Over Author "Fay, Andre P."
135 results on '"Fay, Andre P."'

1. Sex and survival outcomes in patients with renal cell carcinoma receiving first-line immune-based combinations

Author

Incorvaia, Lorena, Monteiro, Fernando Sabino Marques, Massari, Francesco, Park, Se Hoon, Roviello, Giandomenico, Fiala, Ondřej, Myint, Zin W., Kucharz, Jakub, Molina-Cerrillo, Javier, Santini, Daniele, Buttner, Thomas, Poprach, Alexandr, Kopecky, Jindrich, Zeppellini, Annalisa, Pichler, Martin, Buchler, Tomas, Pichler, Renate, Facchini, Gaetano, Fay, Andre Poisl, Soares, Andrey, Manneh, Ray, Iezzi, Laura, Kuronya, Zsofia, Russo, Antonio, Bourlon, Maria T., Bhuva, Dipen, Ansari, Jawaher, Kanesvaran, Ravindran, Grande, Enrique, Buti, Sebastiano, and Santoni, Matteo

Published
2024
Full Text
View/download PDF

2. First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial

Author

Fizazi, Karim, Azad, Arun A., Matsubara, Nobuaki, Carles, Joan, Fay, Andre P., De Giorgi, Ugo, Joung, Jae Young, Fong, Peter C. C., Voog, Eric, Jones, Robert J., Shore, Neal D., Dunshee, Curtis, Zschäbitz, Stefanie, Oldenburg, Jan, Ye, Dingwei, Lin, Xun, Healy, Cynthia G., Di Santo, Nicola, Laird, A. Douglas, Zohren, Fabian, and Agarwal, Neeraj

Published
2024
Full Text
View/download PDF

3. Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study

Author

Azad, Arun A., Fizazi, Karim, Matsubara, Nobuaki, Saad, Fred, De Giorgi, Ugo, Joung, Jae Young, Fong, Peter C.C., Jones, Robert J., Zschäbitz, Stefanie, Oldenburg, Jan, Shore, Neal D., Dunshee, Curtis, Carles, Joan, Fay, Andre P., Lin, Xun, DeAnnuntis, Liza, Di Santo, Nicola, Zielinski, Michael A., and Agarwal, Neeraj

Published
2024
Full Text
View/download PDF

4. Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial

Author

Fizazi, Karim, Azad, Arun A., Matsubara, Nobuaki, Carles, Joan, Fay, Andre P., De Giorgi, Ugo, Joung, Jae Young, Fong, Peter C. C., Voog, Eric, Jones, Robert J., Shore, Neal D., Dunshee, Curtis, Zschäbitz, Stefanie, Oldenburg, Jan, Ye, Dingwei, Lin, Xun, Healy, Cynthia G., Di Santo, Nicola, Laird, A. Douglas, Zohren, Fabian, and Agarwal, Neeraj

Published
2024
Full Text
View/download PDF

5. Circulating tumor cells as a predictor and prognostic tool for metastatic clear cell renal carcinoma: An immunocytochemistry and genomic analysis

Author

Tariki, Milena Shizue, Barberan, Caroline Correia Ghensev, Torres, Jacqueline Aparecida, Ruano, Anna Paula Carreta, Ferreira Costa, Daniela de Jesus, Braun, Alexcia Camila, da Silva Alves, Vanessa, de Cássio Zequi, Stenio, da Costa, Walter Henriques, Fay, André P., Torrezan, Giovana, Carraro, Dirce M., and Domingos Chinen, Ludmilla T.

Published
2024
Full Text
View/download PDF

6. Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial

Author

Agarwal, Neeraj, Azad, Arun A, Carles, Joan, Fay, Andre P, Matsubara, Nobuaki, Heinrich, Daniel, Szczylik, Cezary, De Giorgi, Ugo, Young Joung, Jae, Fong, Peter C C, Voog, Eric, Jones, Robert J, Shore, Neal D, Dunshee, Curtis, Zschäbitz, Stefanie, Oldenburg, Jan, Lin, Xun, Healy, Cynthia G, Di Santo, Nicola, Zohren, Fabian, and Fizazi, Karim

Published
2023
Full Text
View/download PDF

7. Multicenter Database of Patients with Germ-Cell Tumors: A Latin American Cooperative Oncology Group Registry (LACOG 0515)

Author

Bastos, Diogo A., Gongora, Aline Bobato Lara, Dzik, Carlos, Jardim, Denis Leonardo, Piva, Marina, Carcano, Flavio Mavignier, Bertollo, Glaucio, Trindade, Karine, Fontes, Mariane Sousa, Soares, Andrey, Reinert, Tomas, De Cassia Costamilan, Rita, Villarroel, Rodrigo Ughini, Watarai, Gabriel, Gazola, Antonia Angeli, Preto, Daniel D Almeida, Mutti, Haila, Bonalumi dos Santos, Marcela, Mariano, Rodrigo Coutinho, Binotto, Monique, Carvalho, Monique Maciel, Oliveira, Veronica Patrícia da Costa, Gomes, Rafaela, Rebelatto, Taiane F, Schutz, Fabio A., Smaletz, Oren, and Fay, Andre P.

Published
2023
Full Text
View/download PDF

8. A phase II trial of pembrolizumab plus platinum-based chemotherapy as first-line systemic therapy in advanced penile cancer: HERCULES (LACOG 0218) trial.

Author

Maluf, Fernando Cotait, primary, Trindade, Karine, additional, Preto, Daniel D Almeida, additional, Monteiro, Fernando Sabino Marques, additional, Luz, Murilo, additional, Beato, Patricia Milhomem, additional, Bastos, Diogo Assed, additional, Soares, Joao Paulo Holanda, additional, Lopes dos Santos, Victor Marcondes, additional, Werneck De Carvalho, Luis Eduardo, additional, Muniz, David Queiroz Borges, additional, Racy, Douglas, additional, Halabi, Susan, additional, Rebelatto, Taiane Francieli, additional, Werutsky, Gustavo, additional, de Jesus, Rafaela Gomes, additional, and Fay, Andre P., additional

Published
2024
Full Text
View/download PDF

9. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

Author

Park, Se Hoon, van der Heijden, Michiel S., Necchi, Andrea, Castellano, Daniel, Bamias, Aristotelis, Lee, Jae Lyun, De Giorgi, Ugo, Bögemann, Martin, Eigl, Bernhard J., Tsiatas, Marinos, Powles, Thomas, Novikov, Andrey, Skoneczna, Iwona, Mukherjee, Som D., Suarez, Cristina, Westgeest, Hans, Fradet, Yves, Flechon, Aude, Ou, Yen-Chuan, Park, Inkeun, Matveev, Vsevolod, Pérez-Valderrama, Begoña, Cheng, Susanna, Frank, Stephen, Gurney, Howard, Anido, Urbano, Hamzaj, Alketa, Retz, Margitta, Sridhar, Srikala, Scagliotti, Giorgio Vittorio, Voortman, Jens, Alekseev, Boris, Alyasova, Anna, Komyakov, Boris, Dumez, Herlinde, Pavic, Michel, Kimura, Go, Mizokami, Atsushi, Osanto, Susanne, Arranz, Jose Angel, Piersma, Djura, Shin, Sang Joon, Karyakin, Oleg, Delgado, Ignacio, Gonzalez, Jose Luis, Pang, See-Tong, Tran, Anna, Lipatov, Oleg, Su, Wen-Pin, Flaig, Thomas, Alva, Ajjai, Park Kyong, Hwa, Kopyltsov, Evgeny, Almagro, Elena, Domenech, Monserrat, Chang, Yen-Hwa, Sautois, Brieuc, Ravaux, Andre, Aravantinos, Gerasimos, Georgoulias, Vasileios, Mulder, Sasja, Kim, Yu Jung, Kater, Fabio, Chevreau, Christine, Tagawa, Scott, Zalewski, Pawel, Joly, Florence, Loriot, Yohann, Hatiboglu, Gencay, Gianni, Luca, Morelli, Franco, Tambaro, Rosa, Hashimoto, Yasuhiro, Nosov, Alexander, Font, Albert, Rodriguez-Vida, Alejo M., Jones, Robert, Vasudev, Naveen, Srinivas, Sandhya, Zhang, Jingsong, Gil, Thierry, Finch, Daygen, Grimm, Marc-Oliver, Su, Yu-Li, Chowdhury, Simon, Hocking, Christopher, Plas, Eugen, North, Scott, Jensen, Niels Viggo, Theodore, Christine, Imkamp, Florian, Peer, Avivit, Kobayashi, Takashi, Sakai, Hideki, Sassa, Naoto, Yoshimura, Kazuhiro, Aarts, Maureen, Ferreira Castro, Ana, Topuzov, Marlen, Rodriguez, Juan Francisco, Vazquez, Federico Jose, Tsai, Yu-Chieh, Crabb, Simon, Hussain, Syed, Bendell, Johanna, Gross-Goupil, Marine, Gwenaelle, Gravis, Berger, Raanan, Statsenko, Galina, Evans, Linda, Drakaki, Alexandra, Somer, Bradley, Davis, Ian, Lynam, James, Borges, Giuliano, Dettino, Aldo, Fay, André P., Martins, Graziella, Zucca, Luis Eduardo, Agerbaek, Mads, Kalofonos, Haralambos, Rosenbaum, Eli, Enokida, Hideki, Kikukawa, Hiroaki, Nishimura, Kazuo, Tamada, Satoshi, Uemura, Motohide, Lopez, Yamil, Gietema, Jourik, Slojewski, Marcin, Fernandes, Isabel, Smolin, Alexey, Mazhar, Danish, Kalebasty, Arash Rezazadeh, Carthon, Bradley, Loidl, Wolfgang, Franke, Fabio, Girotto, Gustavo, Alimohamed, Nimira, Macfarlane, Robyn, Pappot, Helle, Niegisch, Guenter, Mavroudis, Dimitrios, Sella, Avishay, Porta, Camillo, Ebara, Shin, Nakamura, Motonobu, Obara, Wataru, Okuno, Norihiko, Shinohara, Nobuo, Sugimoto, Mikio, Suzuki, Akitaka, Tokuda, Noriaki, Uemura, Hiroji, Yamaguchi, Akito, Ramirez, Francisco, Rozanowski, Pawel, Wiechno, Pawel, Keam, Bhumsuk, Kislov, Nikolay, Plaksin, Denis, Cicin, Irfan, Kumar, Satish, Galsky, Matthew D., Petrylak, Daniel P., Rosales, Joseph, Vaishampayan, Ulka, Culine, Stephane, Papandreou, Christos, Nara, Taketoshi, Erman, Mustafa, Kreiger, Laurence, Janoski, Juliana, Rosa, Diogo, Siqueira, Mariana, Canil, Christina, Sengelov, Lisa, Tourani, Jean-Marc, Arai, Gaku, Hashine, Katsuyoshi, Kawakita, Mutsushi, Nakaigawa, Noboru, Nomi, Hayahito, Shiina, Hiroaki, Suzuki, Hiroyoshi, Yonese, Junji, Kuri, Roberto, Macedo, Eleazar, Rivera, Samuel, Villalobos Prieto, Alberto, Polakiewicz-Gilowska, Anna, Zaucha, Renata, Lopes, Fabio, Ponomarev, Roman, Pomerantz, Mark, Shariat, Shahrokh, Luk, Cynthia, Lesniewski-Kmak, Krzysztof, van der Heijden, Michiel S, Galsky, Matthew D, Petrylak, Daniel P, Ogawa, Osamu, Lee, Jae-Lyun, Eigl, Bernhard J, Mukherjee, Som D, Suárez, Cristina, Fay, André P, Duran, Ignacio, Wildsmith, Sophie, He, Philip, Angra, Natasha, Gupta, Ashok K, Levin, Wendy, and Bellmunt, Joaquim

Published
2020
Full Text
View/download PDF

11. Plain language summary of the results from the TALAPRO-2 study: Talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer.

Author

Agarwal, Neeraj, Azad, Arun A, Carles, Joan, Fay, Andre P, Matsubara, Nobuaki, Heinrich, Daniel, Szczylik, Cezary, De Giorgi, Ugo, Joung, Jae Young, Fong, Peter C C, Voog, Eric, Jones, Robert J, Shore, Neal D, Dunshee, Curtis, Zschäbitz, Stefanie, Oldenburg, Jan, Lin, Xun, Healy, Cynthia G, Di Santo, Nicola, and Zohren, Fabian

Abstract

What is this summary about? This summary describes the results from the TALAPRO-2 research study (also known as a clinical trial). The TALAPRO-2 study tested the combination of two medicines called talazoparib plus enzalutamide. This combination of medicines was used as the first treatment for adult patients with metastatic castration-resistant prostate cancer. The combination of talazoparib plus enzalutamide was compared with a placebo plus enzalutamide. What is metastatic castration-resistant prostate cancer? Metastatic castration-resistant prostate cancer is a type of cancer that starts in the prostate and has spread to other parts of the body. Castration-resistant means that the cancer continues to grow even when testosterone levels in the blood are reduced to very low levels. Taking medicines to lower testosterone levels in the blood is a standard treatment for men with advanced prostate cancer. What are the aims of the TALAPRO-2 trial? TALAPRO-2 looked at if combining talazoparib plus enzalutamide would increase the length of time patients lived before their cancer got worse or they died compared with a placebo plus enzalutamide. Researchers looked at how treatment affected the size and number of tumors and the length of time before patients needed to change to a new cancer medicine. Researchers also looked at any side effects patients had during the study. What are the key takeaways? A total of 805 patients with metastatic castration-resistant prostate cancer took part in the study. Compared with patients who took a placebo plus enzalutamide, the group of patients who took talazoparib plus enzalutamide had a 37% reduced risk of their cancer getting worse or dying. Some patients had tumors that at the start of the study could be measured with scans. Sixty-two percent of patients who took talazoparib plus enzalutamide had their tumors decrease or shrink to the point that they could no longer be seen on scans versus 44% of patients who took a placebo plus enzalutamide. Patients who took talazoparib plus enzalutamide were more likely to have a longer time before they needed to change to a new cancer medicine. The most common side effects of talazoparib plus enzalutamide were low levels of red blood cells (66% of patients) and neutrophils (36% of patients), and excessive tiredness or exhaustion (34% of patients). Clinical Trial Registration:NCT03395197 (TALAPRO-2) (ClinicalTrials.gov) [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

13. Data from Marital Status, Living Arrangement, and Survival among Individuals with Advanced Prostate Cancer in the International Registry for Men with Advanced Prostate Cancer

Author

Chen, Naiyu, primary, McGrath, Colleen B., primary, Ericsson, Caroline I., primary, Vaselkiv, Jane B., primary, Rencsok, Emily M., primary, Stopsack, Konrad H., primary, Guard, Hannah E., primary, Autio, Karen A., primary, Rathkopf, Dana E., primary, Enting, Deborah, primary, Bitting, Rhonda L., primary, Mateo, Joaquin, primary, Githiaka, Charles W., primary, Chi, Kim N., primary, Cheng, Heather H., primary, Davis, Ian D., primary, Anderson, Simon G., primary, Badal, Simone Ann Marie, primary, Bjartell, Anders, primary, Russnes, Kjell M., primary, Heath, Elisabeth I., primary, Pomerantz, Mark M., primary, Henegan, John C., primary, Hyslop, Terry, primary, Esteban, Emilio, primary, Omlin, Aurelius, primary, McDermott, Ray, primary, Fay, Andre P., primary, Popoola, Ademola Alabi, primary, Ragin, Camille, primary, Nowak, Joel, primary, Gerke, Travis, primary, Kantoff, Philip W., primary, George, Daniel J., primary, Penney, Kathryn L., primary, and Mucci, Lorelei A., primary

Published
2024
Full Text
View/download PDF

14. Supplementary Table 1. from Marital Status, Living Arrangement, and Survival among Individuals with Advanced Prostate Cancer in the International Registry for Men with Advanced Prostate Cancer

Author

Chen, Naiyu, primary, McGrath, Colleen B., primary, Ericsson, Caroline I., primary, Vaselkiv, Jane B., primary, Rencsok, Emily M., primary, Stopsack, Konrad H., primary, Guard, Hannah E., primary, Autio, Karen A., primary, Rathkopf, Dana E., primary, Enting, Deborah, primary, Bitting, Rhonda L., primary, Mateo, Joaquin, primary, Githiaka, Charles W., primary, Chi, Kim N., primary, Cheng, Heather H., primary, Davis, Ian D., primary, Anderson, Simon G., primary, Badal, Simone Ann Marie, primary, Bjartell, Anders, primary, Russnes, Kjell M., primary, Heath, Elisabeth I., primary, Pomerantz, Mark M., primary, Henegan, John C., primary, Hyslop, Terry, primary, Esteban, Emilio, primary, Omlin, Aurelius, primary, McDermott, Ray, primary, Fay, Andre P., primary, Popoola, Ademola Alabi, primary, Ragin, Camille, primary, Nowak, Joel, primary, Gerke, Travis, primary, Kantoff, Philip W., primary, George, Daniel J., primary, Penney, Kathryn L., primary, and Mucci, Lorelei A., primary

Published
2024
Full Text
View/download PDF

17. Marital status, living arrangement, and survival among individuals with advanced prostate cancer in the International Registry for Men with Advanced Prostate Cancer

Author

Chen, Naiyu, primary, McGrath, Colleen B., additional, Ericsson, Caroline I., additional, Vaselkiv, Jane B., additional, Rencsok, Emily M., additional, Stopsack, Konrad H., additional, Guard, Hannah E., additional, Autio, Karen A., additional, Rathkopf, Dana E., additional, Enting, Deborah, additional, Bitting, Rhonda L., additional, Mateo, Joaquin, additional, Githiaka, Charles Waihenya., additional, Chi, Kim N., additional, Cheng, Heather H., additional, Davis, Ian D., additional, Anderson, Simon G., additional, Badal, Simone Ann Marie., additional, Bjartell, Anders, additional, Russnes, Kjell M., additional, Heath, Elisabeth I., additional, Pomerantz, Mark M., additional, Henegan, John C., additional, Hyslop, Terry, additional, Esteban, Emilio, additional, Omlin, Aurelius, additional, McDermott, Ray, additional, Fay, Andre P., additional, Popoola, Ademola Alabi., additional, Ragin, Camille, additional, Nowak, Joel, additional, Gerke, Travis, additional, Kantoff, Philip W., additional, George, Daniel J., additional, Penney, Kathryn L., additional, and Mucci, Lorelei A., additional

Published
2024
Full Text
View/download PDF

19. Exploratory analyses of homologous recombination repair (HRR) gene subgroups and potential associations with secondary efficacy endpoints in the HRR-deficient population from TALAPRO-2.

Author

Zschaebitz, Stefanie, Fizazi, Karim, Matsubara, Nobuaki, Laird, Douglas, Azad, Arun, Shore, Neal D., ButtIgliero, Consuelo, Szczylik, Cezary, Fay, Andre P., Carles, Joan, Jones, Robert J, Voog, Eric, Van Bruwaene, Siska, De Giorgi, Ugo, Yip, Steven M., Di Santo, Nicola, Lin, Xun, Healy, Cynthia G., and Agarwal, Neeraj

Published
2024
Full Text
View/download PDF

20. Post hoc analysis of rPFS and OS from the TALAPRO-2 (TP-2) study: Genomic subgroups based on likelihood of BRCA or HRR gene alteration status.

Author

Shore, Neal D., Agarwal, Neeraj, Azad, Arun, Carles, Joan, Fay, Andre P., Matsubara, Nobuaki, De Giorgi, Ugo, Joung, Jae Young, Fong, Peter C.C., Voog, Eric, Jones, Robert J, Dunshee, Curtis, Zschaebitz, Stefanie, Oldenburg, Jan, Lin, Xun, Healy, Cynthia G., Di Santo, Nicola, Laird, Douglas, Zohren, Fabian, and Fizazi, Karim

Published
2024
Full Text
View/download PDF

21. Patient-reported outcomes (PROs) with talazoparib (TALA) plus enzalutamide (ENZA) vs. placebo (PBO) plus ENZA in men with metastatic castration-resistant prostate cancer (mCRPC): Subgroup analysis of patients with novel hormonal therapy (NHT)...

Author

De Giorgi, Ugo, Azad, Arun, Fizazi, Karim, Matsubara, Nobuaki, Saad, Fred, Joung, Jae Young, Fong, Peter C.C., Jones, Robert J., Zschaebitz, Stefanie, Oldenburg, Jan, Shore, Neal D., Dunshee, Curtis, Carles, Joan, Fay, Andre P., Cislo, Paul, Kirker, Melissa, Healy, Cynthia G., Niyazov, Alexander, and Agarwal, Neeraj

Published
2024
Full Text
View/download PDF

22. Patient reported outcomes (PROs) among patients with metastatic castration-resistant prostate cancer (mCRPC) by homologous recombination repair mutations (HRRm) gene clusters: Findings from the phase 3 TALAPRO-2 study cohort 2.

Author

Fizazi, Karim, Shore, Neal D., Fong, Peter C.C., Azad, Arun, Matsubara, Nobuaki, Saad, Fred, De Giorgi, Ugo, Joung, Jae Young, Jones, Robert J., Zschaebitz, Stefanie, Oldenburg, Jan, Dunshee, Curtis, Carles, Joan, Fay, Andre P., Cislo, Paul, Kirker, Melissa, Healy, Cynthia G., Niyazov, Alexander, and Agarwal, Neeraj

Published
2024
Full Text
View/download PDF

23. Molecular characterization of metastatic penile carcinoma (mPC) in developing countries and its association with clinical outcomes: LACOG 2018 FOUNDATION translational trial.

Author

Monteiro, Fernando Sabino Marques, Alencar Jr, Antonio Machado, Trindade, Karine, Rebelatto, Taiane Francieli, Maluf, Fernando Cotait, Ferreira, Naira Oliveira, Gazola, Antonia Angeli, Barrios, Pablo M., Bellmunt, Joaquim, de Jesus, Rafaela Gomes, Silva, Gyl Eanes Barros, Teixeira Junior, Antonio Augusto Lima, Spiess, Philippe E., and Fay, Andre P.

Published
2024
Full Text
View/download PDF

25. Supplementary Data from Mutations and Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma

Author

Nassar, Amin H., primary, Hamieh, Lana, primary, Gray, Kathryn P., primary, Thorner, Aaron R., primary, Fay, Andre P., primary, Lasseter, Kathryn D., primary, Abou Alaiwi, Sarah, primary, Nuzzo, Pier Vitale, primary, Flippot, Ronan, primary, Krajewski, Katherine M., primary, Signoretti, Sabina, primary, Choueiri, Toni K., primary, and Kwiatkowski, David J., primary

Published
2023
Full Text
View/download PDF

26. Data from The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non–Clear Cell Renal Cell Carcinoma

Author

McKay, Rana R., primary, Bossé, Dominick, primary, Xie, Wanling, primary, Wankowicz, Stephanie A.M., primary, Flaifel, Abdallah, primary, Brandao, Raphael, primary, Lalani, Aly-Khan A., primary, Martini, Dylan J., primary, Wei, Xiao X., primary, Braun, David A., primary, Van Allen, Eliezer, primary, Castellano, Daniel, primary, De Velasco, Guillermo, primary, Wells, J. Connor, primary, Heng, Daniel Y., primary, Fay, Andre P., primary, Schutz, Fabio A., primary, Hsu, JoAnn, primary, Pal, Sumanta K., primary, Lee, Jae Lyun, primary, Hsieh, James J., primary, Harshman, Lauren C., primary, Signoretti, Sabina, primary, Motzer, Robert J., primary, Feldman, Darren, primary, and Choueiri, Toni K., primary

Published
2023
Full Text
View/download PDF

27. Data from Mutations and Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma

Author

Nassar, Amin H., primary, Hamieh, Lana, primary, Gray, Kathryn P., primary, Thorner, Aaron R., primary, Fay, Andre P., primary, Lasseter, Kathryn D., primary, Abou Alaiwi, Sarah, primary, Nuzzo, Pier Vitale, primary, Flippot, Ronan, primary, Krajewski, Katherine M., primary, Signoretti, Sabina, primary, Choueiri, Toni K., primary, and Kwiatkowski, David J., primary

Published
2023
Full Text
View/download PDF

28. Supplementary Data from The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non–Clear Cell Renal Cell Carcinoma

Author

McKay, Rana R., primary, Bossé, Dominick, primary, Xie, Wanling, primary, Wankowicz, Stephanie A.M., primary, Flaifel, Abdallah, primary, Brandao, Raphael, primary, Lalani, Aly-Khan A., primary, Martini, Dylan J., primary, Wei, Xiao X., primary, Braun, David A., primary, Van Allen, Eliezer, primary, Castellano, Daniel, primary, De Velasco, Guillermo, primary, Wells, J. Connor, primary, Heng, Daniel Y., primary, Fay, Andre P., primary, Schutz, Fabio A., primary, Hsu, JoAnn, primary, Pal, Sumanta K., primary, Lee, Jae Lyun, primary, Hsieh, James J., primary, Harshman, Lauren C., primary, Signoretti, Sabina, primary, Motzer, Robert J., primary, Feldman, Darren, primary, and Choueiri, Toni K., primary

Published
2023
Full Text
View/download PDF

31. TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Author

Agarwal, Neeraj, primary, Azad, Arun, additional, Carles, Joan, additional, Fay, Andre P., additional, Matsubara, Nobuaki, additional, Heinrich, Daniel, additional, Szczylik, Cezary, additional, De Giorgi, Ugo, additional, Joung, Jae Young, additional, Fong, Peter C.C., additional, Voog, Eric, additional, Jones, Robert J, additional, Shore, Neal D., additional, Dunshee, Curtis, additional, Zschaebitz, Stefanie, additional, Lin, Xun, additional, Healy, Cynthia G., additional, Di Santo, Nicola, additional, Zohren, Fabian, additional, and Fizazi, Karim, additional

Published
2023
Full Text
View/download PDF

32. Survival outcomes of metastatic castration-resistant prostate cancer in Brazil (LACOG 1818).

Author

Maluf, Fernando Cotait, primary, Martins, Suelen P. S., additional, Silva Neto, Deusdedit Cortêz Vieira, additional, Werutsky, Gustavo, additional, Rinck Jr, Jose Augusto, additional, Bastos, Diogo Assed, additional, Rocha, Roberto Odebrecht, additional, Fay, Andre P., additional, Fernandes, Roni de Carvalho, additional, Girardi, Daniel da Motta, additional, Araujo, Daniel Vilarim, additional, Mota, Augusto C. A., additional, Lara Gongora, Aline Bobato, additional, Fernandes, Bruno Melo, additional, Alves, Ana Caroline Fonseca, additional, Sampaio, Cristina de Deus Anjos Tavares, additional, de Souza, Andréa Lopes Ponte, additional, de Jesus, Rafaela Gomes, additional, Gössling, Gustavo Cartaxo de Lima, additional, and Soares, Andrey, additional

Published
2023
Full Text
View/download PDF

33. A phase II trial of pembrolizumab combined with platinum-based chemotherapy as first-line systemic therapy in advanced penile cancer: HERCULES (LACOG 0218) trial.

Author

Maluf, Fernando Cotait, primary, Trindade, Karine, additional, Preto, Daniel D Almeida, additional, Luz, Murilo de Almeida, additional, Beato, Patricia Milhomem, additional, Bastos, Diogo Assed, additional, Camargo, Anamaria Aranha, additional, Bonorino, Cristina Beatriz Cazabuena, additional, de Jesus, Rafaela Gomes, additional, Monteiro, Fernando, additional, Soares, Joao Paulo Holanda, additional, Werneck De Carvalho, Eduardo Eduardo, additional, Lopes dos Santos, Victor Marcondes, additional, Werutsky, Gustavo, additional, Rebelatto, Taiane Francieli, additional, and Fay, Andre P., additional

Published
2023
Full Text
View/download PDF

34. Characteristics of Long-Term and Short-Term Survivors of Metastatic Renal Cell Carcinoma Treated With Targeted Therapies: Results From the International mRCC Database Consortium

Author

Fay, André P., Xie, Wanling L., Lee, Jae-Lyn, Harshman, Lauren C., Bjarnason, Georg A., Knox, Jennifer J., Ernst, Scott, Wood, Lori, Vaishamayan, Ulka N., Yuasa, Takeshi, Tan, Min-Han, Rha, Sun-Young, Donskov, Frede, Agarwal, Neeraj, Kollmannsberger, Christian K., North, Scott A., Rini, Brian I., Choueiri, Toni K., and Heng, Daniel Y.C.

Published
2015
Full Text
View/download PDF

35. Multicenter Database of Patients with Germ-Cell Tumors: A Latin American Cooperative Oncology Group Registry (LACOG 0515)

Author

Bastos, Diogo A., primary, Gongora, Aline Bobato Lara, additional, Dzik, Carlos, additional, Jardim, Denis Leonardo, additional, Piva, Marina, additional, Carcano, Flavio Mavignier, additional, Bertollo, Glaucio, additional, Trindade, Karine, additional, Fontes, Mariane Sousa, additional, Soares, Andrey, additional, Reinert, Tomas, additional, De Cassia Costamilan, Rita, additional, Villarroel, Rodrigo Ughini, additional, Watarai, Gabriel, additional, Gazola, Antonia Angeli, additional, Preto, Daniel D Almeida, additional, Mutti, Haila, additional, Bonalumi dos Santos, Marcela, additional, Mariano, Rodrigo Coutinho, additional, Binotto, Monique, additional, Carvalho, Monique Maciel, additional, Oliveira, Veronica Patrícia da Costa, additional, Gomes, Rafaela, additional, Rebelatto, Taiane F, additional, Schutz, Fabio A., additional, Smaletz, Oren, additional, and Fay, Andre P., additional

Published
2022
Full Text
View/download PDF

36. Plain language summary of the design of the TALAPRO-2 study comparing talazoparib and enzalutamide versus enzalutamide and placebo in men with metastatic castration-resistant prostate cancer

Author

Agarwal, Neeraj, primary, Azad, Arun, additional, Shore, Neal D, additional, Carles, Joan, additional, Fay, Andre P, additional, Dunshee, Curtis, additional, Karsh, Lawrence Ivan, additional, Paccagnella, Maria Luisa, additional, Santo, Nicola Di, additional, Elmeliegy, Mohamed, additional, Lin, Xun, additional, Czibere, Akos, additional, and Fizazi, Karim, additional

Published
2022
Full Text
View/download PDF

40. Survival analysis of the randomized phase II trial to investigate androgen signaling inhibitors with or without androgen deprivation therapy (ADT) for castration-sensitive prostate cancer: LACOG 0415.

Author

Maluf, Fernando Cotait, primary, Soares, Andrey, additional, Bastos, Diogo Assed, additional, Schutz, Fabio A. B., additional, Cronemberger, Eduardo, additional, Luz, Murilo, additional, Martins, Suelen P. S., additional, Muniz, David Queiroz Borges, additional, Carcano, Flavio Mavignier, additional, Smaletz, Oren, additional, Peixoto, Fábio A, additional, Gomes, Andrea J, additional, Cruz, Felipe Melo, additional, Franke, Fabio, additional, Herchenhorn, Daniel, additional, Gidekel, Rosemarie, additional, Rebelatto, Taiane Francieli, additional, Gomes, Rafaela, additional, Souza, Vinicius Carrera, additional, and Fay, Andre P., additional

Published
2022
Full Text
View/download PDF

41. Genetic determinants of chromatin reveal prostate cancer risk mediated by context-dependent gene regulation

Author

Lack, Nathan Alan (ORCID 0000-0001-7399-5844 & YÖK ID 120842), Baca, Sylvan C.; Singler, Cassandra; Zacharia, Soumya; Seo, Ji-Heui; Morova, Tunc; Hach, Faraz; Ding, Yi; Schwarz, Tommer; Huang, Chia-Chi Flora; Anderson, Jacob; Fay, Andre P.; Kalita, Cynthia; Groha, Stefan; Pomerantz, Mark M.; Wang, Victoria; Linder, Simon; Sweeney, Christopher J.; Zwart, Wilbert; Pasaniuc, Bogdan; Takeda, David Y.; Gusev, Alexander; Freedman, Matthew L., School of Medicine, Lack, Nathan Alan (ORCID 0000-0001-7399-5844 & YÖK ID 120842), Baca, Sylvan C.; Singler, Cassandra; Zacharia, Soumya; Seo, Ji-Heui; Morova, Tunc; Hach, Faraz; Ding, Yi; Schwarz, Tommer; Huang, Chia-Chi Flora; Anderson, Jacob; Fay, Andre P.; Kalita, Cynthia; Groha, Stefan; Pomerantz, Mark M.; Wang, Victoria; Linder, Simon; Sweeney, Christopher J.; Zwart, Wilbert; Pasaniuc, Bogdan; Takeda, David Y.; Gusev, Alexander; Freedman, Matthew L., and School of Medicine

Abstract

Many genetic variants affect disease risk by altering context-dependent gene regulation. Such variants are difficult to study mechanistically using current methods that link genetic variation to steady-state gene expression levels, such as expression quantitative trait loci (eQTLs). To address this challenge, we developed the cistrome-wide association study (CWAS), a framework for identifying genotypic and allele-specific effects on chromatin that are also associated with disease. In prostate cancer, CWAS identified regulatory elements and androgen receptor-binding sites that explained the association at 52 of 98 known prostate cancer risk loci and discovered 17 additional risk loci. CWAS implicated key developmental transcription factors in prostate cancer risk that are overlooked by eQTL-based approaches due to context-dependent gene regulation. We experimentally validated associations and demonstrated the extensibility of CWAS to additional epigenomic datasets and phenotypes, including response to prostate cancer treatment. CWAS is a powerful and biologically interpretable paradigm for studying variants that influence traits by affecting transcriptional regulation. Cistrome-wide association study (CWAS) is an approach for nominating variants that impact traits through effects on chromatin state. CWAS performed on 307 prostate cistromes identifies candidate loci for prostate cancer and androgen-related traits., This work is supported by grants from the PhRMA Foundation and the Kure It Cancer Research Foundation (S.C.B.). The androgen deprivation GWAS was supported in part by the National Cancer Institute of the National Institutes of Health under award numbers U10CA180820, U10CA180794 and UG1CA233180 (C.J.S.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. We are grateful to the E3805: CHAARTED investigators; the patients who participated in the trial; the Prostate Cancer Foundation Mazzone Awards; and Sanofi for partial financial support and supplying docetaxel for early use (C.J.S.). In addition, we acknowledge Public Health Service grants CA180794, CA180820, CA23318, CA66636, CA21115, CA49883, CA16116, CA21076, CA27525, CA13650, CA14548, CA35421, CA32102, CA31946, CA04919, CA107868 and CA184734 (C.J.S.). We are grateful for the generous support of Rebecca and Nathan Milikowsky and Debbie and Bob First (S.C.B.).

Published
2022

43. Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 phase III study design

Author

Agarwal, Neeraj, primary, Azad, Arun, additional, Shore, Neal D, additional, Carles, Joan, additional, Fay, Andre P, additional, Dunshee, Curtis, additional, Karsh, Lawrence Ivan, additional, Paccagnella, Maria Luisa, additional, Santo, Nicola Di, additional, Elmeliegy, Mohamed, additional, Lin, Xun, additional, Czibere, Akos, additional, and Fizazi, Karim, additional

Published
2022
Full Text
View/download PDF

44. “Non-metastatic, Castration-resistant Prostate Cancer: Diagnostic and Treatment Recommendations by an Expert Panel from Brazil”

Author

Jardim, Denis L., Gonçalves e Silva, Adriano, Pompeo, Alexandre Saad Fere Lima, Sarkis, Alvaro Sadek, Cardoso, Ana Paula Garcia, Sasse, Andre Deeke, Fay, Andre Poisl, Soares, Andrey, Pompeo, Antonio Carlos Lima, Carneiro, Arie, Kann, Ariel Galapo, Fogassa, Camilla, De Freitas, Celso Heitor, Chade, Daher Cezar, Herchenhorn, Daniel, De Almeida, Daniel Vargas Pivato, Da Rosa, Diogo Augusto Rodrigues, Wiermann, Evanius Garcia, Schutz, Fabio Augusto Barros, Kater, Fabio Roberto, De Moura, Fernando, Korkes, Fernando, Meyer, Fernando, De Oliveira, Fernando Nunes Galvao, Sabino, Fernando, Almeida, Gilberto Laurino, Avanço, Guilherme, Guimaraes, Gustavo Cardoso, Lemos, Gustavo Caserta, Carvalhal, Gustavo Franco, Kim, Hanna, Morbeck, Igor Protzner, Campagnari, Joao Carlos, Rinck, Jose Augusto, Da Ponte, José Ricardo Tuma, Da Trindade, Karine Martins, Atem, Leonardo, Borges, Leonardo, Nogueira, Lucas Mendes, Batista, Lucas Teixeira e Aguiar, Maia, Manuel Caitano, Sadi, Marcus Vinicius, Rocha, Maria Alzira Almeida, Luz, Murilo De Almeida, Smaletz, Oren, Lages, Paulo Sergio Moraes, Matuda, Raquel Midori Koga, Reis, Rodolfo Borges Dos, Indio, Rodrigo Frota, Fernandes, Roni De Carvalho, Cavallero, Sandro Roberto, Souza, Vinicius Carrera, Busato, Wilson, Alfer, Wladimir, and Maluf, Fernando

Abstract

Non-metastatic, castration-resistant prostate cancer (nmCRPC) is an important clinical stage of prostate cancer, prior to morbidity and mortality from clinical metastases. In particular, the introduction of novel androgen-receptor signaling inhibitors (ARSi) has changed the therapeutic landscape in nmCRPC. Given recent developments in this field, we update our recommendations for the management of nmCRPC.

Published
2023
Full Text
View/download PDF

45. TALAPRO-2: A phase 3 randomized study of enzalutamide (ENZA) plus talazoparib (TALA) versus placebo in patients with new metastatic castration-resistant prostate cancer (mCRPC).

Author

Agarwal, Neeraj, primary, Azad, Arun, additional, Shore, Neal D., additional, Carles, Joan, additional, Fay, Andre P., additional, Dunshee, Curtis, additional, Karsh, Lawrence Ivan, additional, Paccagnella, Maria Luisa, additional, Di Santo, Nicola, additional, Elmeliegy, Mohamed, additional, Lin, Xun, additional, Niyazov, Alexander, additional, Czibere, Akos, additional, and Fizazi, Karim, additional

Published
2021
Full Text
View/download PDF

46. Clinical-pathological characterization and outcomes of metastatic urothelial cancer in Latin America: Retrospective and translational multicenter database (LACOG 1518).

Author

Souza, Vinicius Carrera, primary, Luz, Murilo, additional, Bastos, Diogo Assed, additional, Freitas, Marcelo Roberto Pereira, additional, Dauster Pereira E Silva, Breno, additional, Monteiro, Fernando Sabino M., additional, Fernandes, Roni, additional, Caitano, Manuel, additional, Trindade, Karine, additional, Nogueira, Lucas, additional, Herchenhorn, Daniel, additional, Sade, Juan, additional, Nunes Galvão de Oliveira, Fernando, additional, Fay, Andre P., additional, Werutsky, Gustavo, additional, Maluf, Fernando C., additional, Fabricio, Vanessa Carvalho, additional, Gidekel, Rosemarie, additional, Pacheco, Patricia, additional, and Soares, Andrey, additional

Published
2021
Full Text
View/download PDF

47. A phase III trial of capivasertib and abiraterone versus placebo and abiraterone in patients with de novo metastatic hormone-sensitive prostate cancer characterized by PTEN deficiency (CAPItello-281).

Author

Fizazi, Karim, primary, George, Daniel J., additional, De Santis, Maria, additional, Clarke, Noel, additional, Fay, Andre P., additional, Uemura, Hirotsugu, additional, Grinsted, Lynda, additional, Rooney, Claire, additional, Verheijen, Remy B, additional, Anjum, Rana, additional, Foxley, Andrew, additional, and Morris, Thomas, additional

Published
2021
Full Text
View/download PDF

48. Health-related quality-of-life (HRQoL) analysis from a randomized phase II trial of androgen signaling inhibitors with or without androgen deprivation therapy (ADT) for castration-sensitive prostate cancer: LACOG 0415.

Author

Soares, Andrey, primary, Bastos, Diogo Assed, additional, Schutz, Fabio A. B., additional, Cronemberger, Eduardo, additional, Luz, Murilo, additional, Martins, Suelen P. S., additional, Muniz, David Queiroz Borges, additional, Carcano, Flavio Mavignier, additional, Smaletz, Oren, additional, Peixoto, Fábio A, additional, Gomes, Andrea Juliana, additional, Cruz, Felipe Melo, additional, Franke, Fabio Andre, additional, Herchenhorn, Daniel, additional, Gidekel, Rosemarie, additional, Rebelatto, Taiane Francieli, additional, Gomes, Rafaela, additional, Souza, Vinicius Carrera, additional, Fay, Andre P., additional, and Maluf, Fernando C., additional

Published
2021
Full Text
View/download PDF

49. Abstract PS7-89: The socioeconomic impact of breast cancer in Brazil: An analysis of AMAZONA III cohort study

Author

Werutsky, Gustavo, primary, Rosa, Daniela Dornelles, additional, Barrios, Carlos, additional, Cronemberger, Eduardo, additional, Queiroz, Geraldo, additional, Bines, Jose, additional, Rosa, Mahira Lopes, additional, Gomes, Rafaela, additional, Heck, Ana P, additional, Freitas, Laura, additional, da Silva, Arthur F, additional, Rodrigues, Matheus, additional, Fay, Andre P, additional, and Simon, Sergio, additional

Published
2021
Full Text
View/download PDF

50. A Systematic Review and Meta-Analysis of the Role of Immune Checkpoint Inhibitors (ICI) as Adjuvant Treatment for Localized High-Risk Muscle-Invasive Urothelial Carcinoma (MIUC)

Author

Monteiro, Fernando Sabino M., Soares, Andrey, Souza, Vinicius Carrera, Sperandio, Rubens Copia, Grande, Enrique, Santoni, Matteo, Fay, Andre Poisl, and Sasse, Andre Deeke

Abstract

•Systemic adjuvant chemotherapy for muscle-invasive bladder carcinoma is controversial.•Systemic adjuvant chemotherapy for muscle-invasive upper tract urothelial carcinoma improves disease-free survival, however with considerable toxicity.•Systemic immune checkpoint inhibitors (ICI) were evaluated in the adjuvant treatment setting with lower risk of toxicity, however with conflicting clinical benefit.•After meta-analysis of the ICI available data in the adjuvant setting there was no clinical benefit associate.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results